StoneX Group’s Redhill Biopharma RDHL Stock Holding History

StoneX Group’s Portfolio RDHL Stock Details RDHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,481	Closed	-$10.8K	–	1550
2026 Q1	$10.8K	Buy	+14,481	New	+$15.3K	﹤0.01%	847

Other funds holding RDHL

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

StoneX Group's RDHL Position: Q2 2026 in Review

StoneX Group sold out of Redhill Biopharma (RDHL) in Q2 2026, closing a stake of 14,481 shares — an estimated $10.8K sold.

StoneX Group first reported a position in RDHL in Q1 2026 and held it in 1 quarter. The position peaked at $10.8K in Q1 2026. 14 funds tracked by Wall St. Rank hold RDHL as of Q2 2026.

StoneX Group reported no remaining Redhill Biopharma position as of Q2 2026 after selling out during the quarter.
StoneX Group sold 14,481 Redhill Biopharma shares in Q2 2026, an estimated $10.8K.
StoneX Group first reported a position in Redhill Biopharma in Q1 2026 and held it in 1 quarter.
StoneX Group's Redhill Biopharma position peaked at $10.8K in Q1 2026.
14 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.